Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



# 山東威高集團醫用高分子製品股份有限公司 Shandong Weigao Group Medical Polymer Company Limited<sup>\*</sup>

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1066)

## PROPOSED SPIN-OFF AND SEPARATE LISTING OF SHANDONG WEIGAO ORTHOPEDIC DEVICE COMPANY LIMITED ON THE SCI-TECH BOARD

Reference is made to the announcement of the Company dated 30 December 2019 (the "Announcement") in relation to the proposed spin-off and listing of ordinary shares of Weigao Ortho. Unless otherwise defined, terms used in this announcement shall have the same meanings in the Announcement.

#### **PROPOSED SPIN-OFF**

The Company proposes to spin-off and separately list the ordinary shares of Weigao Ortho on the science and technology innovation board on the Shanghai Stock Exchange ("Sci-Tech Board").

The Board announces that on 11 June 2020, Weigao Ortho submitted an application to the Shanghai Stock Exchange for the proposed listing on the Sci-Tech Board (the "**Proposed Listing**").

Currently, the Company, directly and indirectly, holds approximately 80.53% equity interest in Weigao Ortho. Upon completion of the Proposed Listing on the Sci-Tech Board, it is expected that Weigao Ortho will remain as a subsidiary of the Company.

<sup>\*</sup> For identification purpose only

The Proposed Listing on the Sci-Tech Board is conditional upon, among other things, the approval of the CSRC, the Shanghai Stock Exchange and the Hong Kong Stock Exchange and completion of the proposed initial public offering of the ordinary shares of Weigao Ortho (the "**Offering**"). The terms of the Offering, including the size and price range of the Offering, and the timetable of the Proposed Listing have not yet been fixed as at the date of this announcement.

#### **INFORMATION ON WEIGAO ORTHO**

Weigao Ortho is principally engaged in the manufacturing and sale of orthopaedic implantable medical device including spinal, trauma and joint products. It also produces surgical instruments and tools for spine, trauma, and joint orthopedic implant surgery.

#### LISTING RULES IMPLICATIONS

As the equity interest of the Company in Weigao Ortho is expected to decrease upon completion of the Proposed Listing on the Sci-Tech Board, the Proposed Listing will constitute a deemed disposal of the Company under Chapter 14 of the Listing Rules. It is currently expected that the highest applicable percentage ratio in respect of the Proposed Listing on the Sci-Tech Board will be more than 5% but less than 25%. As such, the Proposed Listing on the Sci-Tech Board is subject to the announcement and reporting requirements, but exempt from shareholders' approval under Chapter 14 of the Listing Rules.

The Proposed Listing also constitutes a spin-off of Weigao Ortho under Practice Note 15 of the Listing Rules. The Company has submitted an application to the Hong Kong Stock Exchange in relation to the Proposed Listing on the Sci-Tech Board. As at the date of this announcement, the Hong Kong Stock Exchange is in the process of reviewing the application and approval in relation to the spin-off has not been granted.

#### GENERAL

The Company will comply with the applicable requirements under the Listing Rules and make further announcement(s) as and when appropriate.

Shareholders of the Company and potential investors should note the Proposed Listing on the Sci-Tech Board is subject to, inter alia, the prevailing market conditions and approvals from relevant authorities, including the CSRC, the Shanghai Stock Exchange and the Hong Kong Stock Exchange. Accordingly, shareholders of the Company and potential investors should be aware that the Proposed Listing on the Sci-Tech Board may or may not proceed. Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.

### By Order of the Board Shandong Weigao Group Medical Polymer Company Limited Zhang Hua Wei Chairman

Weihai, Shandong, the PRC, 11 June 2020

As at the date hereof, the Board comprises of:

Mr. Zhang Hua Wei (Executive Director)
Mr. Long Jing (Executive Director)
Mr. Wang Yi (Executive Director)
Mr. Gong Jian Bo (Executive Director)
Mrs. Zhou Shu Hua (Non-executive Director)
Mr. Lo Wai Hung (Independent non-executive Director)
Mrs. Fu Ming Zhong (Independent non-executive Director)
Mrs. Wang Jin Xia (Independent non-executive Director)